News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe
- Roclanda ® Achieves Non-Inferiority to Ganfort ® - - Mercury 3 Performance Exceeds Prior Phase 3 Trials - DURHAM, N.C. --(BUSINESS WIRE)--Sep. 24, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 15, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 8, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Year-to-Date Net Revenues of $38.4 Million Increased 44% over 2019 Positive Phase 2 Topline Results for AR-1105 Implant Indicate up to Six-Month Sustained Release AR-15512 Trial for Dry Eye, COMET-1, Set to Initiate this Year Conference Call and Webcast Today, August 6 th , at 5:00 p.m.
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 30, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 27, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 11, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Conference Call and Webcast Today, May 6 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--May 6, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--May 5, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and
View HTML
TOP